Placebo for ibrexafungerp 250 mg (tablet) clinical trials

A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole (MARIO)

This study looks at new treatments for serious fungal infections called candidemia and invasive candidiasis. We are comparing a new medicine, ibrexafungerp, with an existing one, fluconazole, to see which works better and is safer after initial treatment with another antifungal.